Fosun International announced on Friday that the Hong Kong Stock Exchange has granted approval for the proposed spin‑off and separate listing of its resort‑operator subsidiary, ClubMed Lifestyle. The approval clears a key regulatory hurdle, allowing the Chinese conglomerate to move forward with an initial public offering (IPO) for the unit.
Details of the planned listing
In an exchange filing, Fosun said the exact terms of the IPO have not yet been finalised. Earlier Reuters reporting suggested the share sale could raise more than $500 million and might occur as early as the end of this year or in early 2027. The company’s shares rose modestly after the news, up 0.6% at 0233 GMT, after having peaked at a 0.9% gain earlier in the session on Monday.
ClubMed’s global footprint
ClubMed, founded in 1950, operates over 60 beach and mountain resorts across 25 countries, offering all‑inclusive vacations that cover accommodation, meals, drinks and activities. Fosun acquired the brand in February 2015 for roughly €917 million (about $1.06 billion at the time). The spin‑off aims to unlock value for shareholders by separating the resort business from Fosun’s broader portfolio of investments.
Implications for investors
The approval signals confidence from Hong Kong regulators in the viability of the spin‑off and may attract both domestic and international investors seeking exposure to the leisure and tourism sector. With travel demand rebounding globally, the timing could be favourable for a successful public offering.
Fosun’s broader strategy
Fosun International, a diversified Chinese conglomerate, has been actively reshaping its asset base through strategic divestitures and listings. The ClubMed spin‑off aligns with its ongoing effort to streamline operations and focus on high‑growth segments.
While the exact pricing and timeline remain to be confirmed, market participants will be watching closely for further details from Fosun and the Hong Kong Stock Exchange in the coming months.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
